RC101

N/A

Report date: 2022/11/04 13:51:02

Base Information

Drug NameRC101
Drug Alias NameRC101
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesRuishengke Biopharmaceutical (Shanghai) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRuishengke Biopharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A